Page 49 - Mployee Wellness Programs News Today

A higher share of Medicaid beneficiaries rate their physical and mental health as fair or poor compared to adults with Medicare, employer-sponsored insurance or Marketplace coverage, according to a new KFF report. However, 83% of Medicaid enrollees gave their health insurance a positive rating.

Medical chatbots have the potential to shape the future of healthcare data retrieval and decision-making support. But this can’t become a reality unless precautions are taken to make sure the answers are both grounded in reality and extracted from reliable sources.

By streamlining front-end processes, reducing errors, and ensuring prompt service delivery, AI and automation not only boost the patient experience but also optimize revenue streams.

For the November episode, we discuss some recent executive hires and departures occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Jeff Good, who just became Northwestern Medicine’s first chief sustainability executive.

Seniors are mostly still interested in $0 premium Medicare Advantage plans, according to a new eHealth report. However, slightly fewer seniors are choosing these plans compared to previous years.

Novo Nordisk's planned expansion will more than double the footprint of its France production site, bringing new capacity for manfacturing GLP-1 drugs for metabolic conditions. The location is already one of the company’s largest for making diabetes products.

One investor is most interested in mental health startups that focus on high acuity care, while another wants to see companies that are built with the end-user in mind, they shared during recent interviews.

At RSNA 2023, healthcare AI startup Paige announced a partnership with Nuance to launch what the companies say is “the largest digital consultation network in pathology." Paige’s digital pathology tools will be embedded into PowerShare, Nuance's nationwide image sharing network with the goal of connecting more pathology labs to expert second opinions.

SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.

As IRA provisions are activated, the law’s impact on biologics and biosimilars will become more apparent. By using both the carrot and the stick, the IRA may finally bolster the market, increasing uptake of biosimilars to benefit patients and help lower costs.